Taft partners Stephen Auten, Joseph M. Bennett-Paris, Ph.D. and Richard T. Ruzich authored chapters in the ABA Publishing book Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio. Ruzich and Bennett-Paris authored Chapter 2, titled “Pre-Clinical R&D.” Auten authored Chapter 22, titled “Citizen Petitions,” which examines how ANDA sponsors can gain a competitive advantage by using this regulatory process in addition to the typical patent litigation framework.
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 5,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Dr. Bennett-Paris practices in Atlanta and Chicago. For 15 years, he has counseled clients in all areas of patent law, including patent prosecution, non-infringement, patentability, freedom-to-operate, invalidity and licensing. His practice primarily focuses on biotechnology, pharmaceutical, chemistry and, most recently, biosimilars. His practice also includes copyright matters and entertainment law, particularly with regard to the music and publishing industries.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilars sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.
For more information or to order the book, click here.